McKesson to acquire Genospace from SCRI.

Synopsis

McKesson, a diversified healthcare services provider, agreed to acquire Genospace, a personalized medicine platform, from Sarah Cannon Research Institute, a clinical trials facility. Financial terms were not disclosed.

Principals

target

GENOSPACE

bidder

Mckesson Corporation

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

mick correll

CEO at GENOSPACE

Manager

target

Deal

n/a

Total Value

Bidder Team (1)

brian tyler

CEO at MCKESSON CORPORATION

Manager

bidder

Deals

£ 3.82 B

Total Value

Vendor Team (1)

dee anna smith

CEO at SARAH CANNON RESEARCH INSTITUTE

Manager

vendor

Deals

n/a

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy